Bicycle Therapeutics
BCYC
54 hedge funds and large institutions have $377M invested in Bicycle Therapeutics in 2021 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 16 increasing their positions, 13 reducing their positions, and 3 closing their positions.
500% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 3
161% more capital inflows, than outflows
Capital inflows: $48.7M | Capital outflows: $18.7M
38% more funds holding
Funds holding: 39 → 54 (+15)
23% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 13
3.37% more ownership
Funds ownership: 38.85% → 42.22% (+3.4%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Eventide Asset Management
Boston,
Massachusetts
|
+$22.7M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$6.9M |
| 3 |
Janus Henderson Group
London,
|
+$4.72M |
| 4 |
Dorsey Wright & Associates
Pasadena,
California
|
+$3.8M |
| 5 |
Morgan Stanley
New York
|
+$1.93M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Atlas Venture Advisors
Boston,
Massachusetts
|
-$9.22M |
| 2 |
Marshall Wace North America
New York
|
-$2.74M |
| 3 |
Logos Global Management
San Francisco,
California
|
-$2.57M |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
-$892K |
| 5 |
Verition Fund Management
Greenwich,
Connecticut
|
-$854K |
BCYC Hedge Fund Activity: Q2 2021 in Review
54 of the 5,769 institutional investors tracked by Wall St. Rank reported a position in Bicycle Therapeutics (BCYC) for Q2 2021, worth a combined $377M — up 10% from $341M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new BCYC positions and 3 closed out — a net gain of 15 holders — while 16 added to existing stakes and 13 trimmed.
The largest buyer was Eventide Asset Management, adding an estimated $22.7M. The largest seller was Atlas Venture Advisors, cutting an estimated $9.22M.
- 54 institutional investors held Bicycle Therapeutics (BCYC) as of Q2 2021, up from 39 in Q1 2021.
- Funds reported $377M of Bicycle Therapeutics stock for Q2 2021, up 10% quarter-over-quarter.
- 18 funds opened new Bicycle Therapeutics positions in Q2 2021 and 3 closed out, a net change of +15 holders.
- The largest Bicycle Therapeutics buyer in Q2 2021 was Eventide Asset Management, an estimated $22.7M added.
- The largest Bicycle Therapeutics seller in Q2 2021 was Atlas Venture Advisors, an estimated $9.22M sold.
Based on aggregated 13F filings for Q2 2021.